OphthaliX announces issuance of Chinese
Patent for the treatment of Dry Eye Disorders
Carson City, Nevada, February
21, 2012 – OphthaliX (OTCBB: OPLI) announced
that the Chinese State Intellectual Property Office (SIPO) issued a Certificate
of Patent Invention for Chinese Patent Application No. 200680047569.7 entitled “Adenosine
A3 receptor agonists for the treatment of dry eye disorders”. This patent is related
to OphthaliX drug candidate CF101 and will grant OphthaliX exclusive rights for
the use of CF101 for the treatment of dry eye syndrome in the People’s Republic
of China untill Feb 2026.
Prof. Pnina Fishman, interim CEO and Chairman
of OphthaliX commented: "We are delighted that the Chinese SIPO granted
us this important patent covering the use of CF101 for dry eye syndrome in
China, reflecting the innovation of CF101 in the ophthalmology field. We are
currently enrolling patients for the ongoing phase 3 multinational study of
this pioneered oral drug for the treatment of Dry Eye Syndrome".
About OphthaliX Inc.
OphthaliX Inc. is an advanced
clinical-stage biopharmaceutical company focused on developing therapeutic
products for the treatment of ophthalmic disorders. OphthaliX's product candidate,
CF101, is being developed to treat three ophthalmic indications: dry eye
syndrome; glaucoma and uveitis.
About
CF101
CF101,
an A3 adenosine receptor agonist, is a novel, first in class, small molecule,
orally bioavailable drug with a proven efficacy in Phase 2 clinical studies and
an excellent safety profile. CF101 is currently developed for ophthalmic
indications. including dry eye syndrome (Phase 3), glaucoma (Phase 2) and
Uveitis. CF101 is also developed for the treatment of autoimmune inflammatory
diseases including rheumatoid arthritis (Phase 2b) and psoriasis (Phase 2/3).
About
CF101 Dry Eye Syndrome Phase 3 Study
The
study is a phase 3 clinical study of the safety and efficacy of CF101, daily
administered orally, in patients with moderate-to-severe Dry Eye Syndrome. This
multi-center clinical trial is conducted in the United States, Europe and
Israel. The randomized, double-masked clinical trial will include 231 patients
who will be randomized to receive 2 doses of CF101 and Placebo, for a period of
24 weeks. The primary efficacy endpoint
will be complete clearing of corneal staining.
Contact:
Pnina Fishman, Interim Chief Executive
Officer
Tel: +972-3-9241114
Email: pnina@ophthalix.com
This release contains forward-looking statements regarding OphthaliX’s
future plans and expected performance based on assumptions the Company believes
to be reasonable. A number of risks and uncertainties could cause actual
results to differ materially from these statements, including, without
limitation, the success rate of business development efforts and the timeliness
of development activities, and other risk factors described from time to time
in the Company’s reports filed with the SEC. In addition, the Company
operates in an industry sector where securities values are highly volatile and
may be influenced by economic and other factors beyond the Company’s control. OphthaliX undertakes no obligation to
publicly update these forward-looking statements, whether as a result of new
information, future events or otherwise.